CCL2 and breast cancer: The activities of luciferase reporter constructs containing deletion variants of the CCL2 promoter were assessed in MDA-MB-231 breast cancer cells in the presence or absence of TGF-β1 (10 ng/mL, 24 h), (Fig. 3).